The company is divesting its Life Sciences & Healthcare segment for $600 million to Altaris, sharpening its focus on core segments and improving its financial profile. The deal is expected to close by year-end, with proceeds used to reduce debt and enhance recurring revenue mix.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.